Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06910072 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TNBC）

Study acronym: UPGRADE-TNBC
StatusEnrolling by Invitation
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 8 months later Oct 1, 2026 → Jun 1, 2027
See other at-risk trials from Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Record History

  1. Re-verified, no change to tracked fieldsv3
  2. Primary completion pushed from Oct 1, 2026 to Jun 1, 2027 Enrolling by invitation only · Start date changed from estimate of Apr 2, 2025 to Jul 21, 2025 · Site contact updated · 1 morev2 Show 4 more changesShow less
    • Enrolling by invitation only
    • Start date changed from estimate of Apr 2, 2025 to Jul 21, 2025
    • Site contact updated
    • Study title revised

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective, single-arm, multicenter study to observe and evaluate the efficacy and safety of paclitaxel polymeric micelles and carboplatin in combination with iparomilimab and tuvonralimab in neoadjuvant therapy for triple-negative breast cancer. The main endpoint of the study is pCR, 32 patients are scheduled to be enrolled.
Trial Details
NCT Number NCT06910072
Lead Sponsor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions Triple-Negative Breast Cancer (TNBC), Neoadjuvant Therapy
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov